Regenxbio Inc (RGNX) SVP Curran Simpson Sells 30,000 Shares

Regenxbio Inc (NASDAQ:RGNX) SVP Curran Simpson sold 30,000 shares of Regenxbio stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $33.03, for a total transaction of $990,900.00. Following the completion of the transaction, the senior vice president now directly owns 69,500 shares of the company’s stock, valued at $2,295,585. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Curran Simpson also recently made the following trade(s):

  • On Thursday, December 7th, Curran Simpson sold 21,890 shares of Regenxbio stock. The stock was sold at an average price of $30.04, for a total transaction of $657,575.60.
  • On Monday, December 4th, Curran Simpson sold 110 shares of Regenxbio stock. The stock was sold at an average price of $30.00, for a total transaction of $3,300.00.
  • On Monday, November 27th, Curran Simpson sold 2,000 shares of Regenxbio stock. The stock was sold at an average price of $29.31, for a total transaction of $58,620.00.

Regenxbio Inc (RGNX) traded up $0.60 during mid-day trading on Thursday, hitting $34.60. 183,500 shares of the company were exchanged, compared to its average volume of 281,467. Regenxbio Inc has a 52-week low of $16.30 and a 52-week high of $36.10. The stock has a market cap of $1,048.04, a PE ratio of -12.81 and a beta of -0.85.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.04. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. The firm had revenue of $1.34 million during the quarter. analysts anticipate that Regenxbio Inc will post -2.71 EPS for the current year.

A number of equities analysts have commented on the stock. Raymond James Financial initiated coverage on shares of Regenxbio in a research note on Thursday, October 12th. They set an “outperform” rating and a $39.00 price target for the company. Bank of America reaffirmed a “buy” rating and set a $38.00 price target (up from $33.00) on shares of Regenxbio in a research note on Monday, October 9th. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Wednesday, October 18th. Chardan Capital reaffirmed a “buy” rating on shares of Regenxbio in a research note on Monday, December 11th. Finally, BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Regenxbio presently has an average rating of “Buy” and a consensus price target of $42.43.

Institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. boosted its position in Regenxbio by 1,042.8% in the 2nd quarter. Citigroup Inc. now owns 29,348 shares of the biotechnology company’s stock valued at $580,000 after buying an additional 26,780 shares during the period. Goldman Sachs Group Inc. boosted its position in Regenxbio by 222.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 113,906 shares of the biotechnology company’s stock valued at $2,250,000 after buying an additional 78,606 shares during the period. TIAA CREF Investment Management LLC boosted its position in Regenxbio by 33.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 74,175 shares of the biotechnology company’s stock valued at $1,465,000 after buying an additional 18,647 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Regenxbio by 32.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 97,695 shares of the biotechnology company’s stock valued at $1,930,000 after buying an additional 23,971 shares during the period. Finally, Redmile Group LLC boosted its position in Regenxbio by 35.4% in the 2nd quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock valued at $33,944,000 after buying an additional 449,540 shares during the period. 68.73% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/12/28/regenxbio-inc-rgnx-svp-curran-simpson-sells-30000-shares.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

What are top analysts saying about Regenxbio? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regenxbio and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit